Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 2500 participants.

Also called NCT07739888

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,500 participants (planned count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07739888
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07739888. Allocation not applicable; no masking; primary purpose treatment. Start 2027-12-30 (anticipated); primary completion 2030-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the effIcacy and Safety of Abelacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral Anticoagulation
Acronym
LILAC-TIMI 76
Condition
Atrial Fibrillation (AF)
Intervention (Biological)
Abelacimab
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct07739888
Content hash
db5cd7d06176f39e3f01b2b73fa5cd6eec1e771f3cc9e69c0c0ad7d9f0b259e0